Abceutics, an I-Corps alumni company based in Buffalo NY, was acquired by Merck, a global leader in biopharmaceuticals, for a potential consideration of up to $208 million. The acquisition includes Abceutics’ innovative Payload-Binding Selectivity Enhancer (PBSE) technology, which is designed to prevent the delivery of highly toxic anticancer agents to healthy cells.
